

treatment of symptoms or pathologies associated with androgen signaling” containing claims 25-31. (Paper No. 20070507 at 2.)

In accordance with restriction practice, the subject matter of claims 25-31 (Group II) is hereby elected for prosecution with traverse.


In addition, the Examiner issued a requirement to “elect a single species from a various instantly claimed compounds or either a specific mixture of the various claimed compounds of claim 4.” (Paper 20070507 at 3.) We note that the claims elected above for prosecution (claims 25-31) do not contain a recitation as in claim 4. Thus, it does not appear that an election of a single compound from claim 4 is required in order to examine claims 25-31. Thus, applicants respectfully submit that the requirement for an election of species should be withdrawn.

However, in accordance with election of species practice genistein aglycone, genistein glucosides, genistein sulfates, genistein glucuronides, or a mixture thereof is elected for purposes of Examination with traverse.

Application No.: 10/537,452
Response Dated: June 14, 2007
Reply to Office Action Dated: May 14, 2007

If the Examiner has any questions regarding this paper, please contact
the undersigned attorney.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 14, 2007.


Stephen J. Brown, Reg. No. 43,519

Respectfully submitted,

By: 

Stephen J. Brown
Registration No. 43,519
BRYAN CAVE LLP
1290 Avenue of the Americas
New York, NY 10104-3300
Phone: (212) 541-2000
Fax: (212) 541-4630